401 related articles for article (PubMed ID: 23224736)
1. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
3. Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage.
Deng H; Gao Y; Trappetti V; Hertig D; Karatkevich D; Losmanova T; Urzi C; Ge H; Geest GA; Bruggmann R; Djonov V; Nuoffer JM; Vermathen P; Zamboni N; Riether C; Ochsenbein A; Peng RW; Kocher GJ; Schmid RA; Dorn P; Marti TM
Cell Mol Life Sci; 2022 Jul; 79(8):445. PubMed ID: 35877003
[TBL] [Abstract][Full Text] [Related]
4. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.
Sudhir PR; Chen CH; Pavana Kumari M; Wang MJ; Tsou CC; Sung TY; Chen JY; Chen CH
Mol Cell Proteomics; 2012 Oct; 11(10):901-15. PubMed ID: 22761399
[TBL] [Abstract][Full Text] [Related]
5. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
Raparia K; Villa C; Raj R; Cagle PT
Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
[TBL] [Abstract][Full Text] [Related]
6. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
7. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.
Sunaga N; Kaira K; Tomizawa Y; Shimizu K; Imai H; Takahashi G; Kakegawa S; Ohtaki Y; Nagashima T; Kasahara N; Kawashima O; Hisada T; Saito R; Yamada M
Br J Cancer; 2014 Apr; 110(8):2047-53. PubMed ID: 24577055
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
10. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
11. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
13. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
[TBL] [Abstract][Full Text] [Related]
16. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
19. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutant allele-specific imbalance in lung adenocarcinoma.
Chiosea SI; Sherer CK; Jelic T; Dacic S
Mod Pathol; 2011 Dec; 24(12):1571-7. PubMed ID: 21743433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
